PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 to detect PD-L1 protein in FFPE tissue specimens using EnVision FLEX visualization system on Autostainer Link 48. It detects PD-L1 expression with a dynamic range of tumor-positive (TPS) 0-100% and combined positive score (CPS) 0-10+.
Cancers include lung cancer, gastric cancer, urothelial cancer, cervical cancer etc.
Sample types: FFPE Block or 5 x 4μm unstained FFPE slides
Turnaround time: 8 working days upon sample arrival
Why use PD-L1 IHC 22C3?
Immuno-Oncology(IO) treatment could be considered.
Why does PD-L1 matter?
In normal circumstance, our T cells can detect cancer cells and activate the body’s defense mechanism to attack the cancer cells. However, some tumor cells can mimic normal cells by upregulating the expression of PD-L1 as a mechanism to evade the body natural response. As a result, T cells will stop attacking the cancer cells.
The purpose of our test is to evaluate the proportion of PD-L1 positive cells.
-Because clinical studies have proven that certain proportion of
PD-L1 leads to improved clinical outcomes in response to IO therapies.